Nektar Therapeutics (NKTR)
1.65
+0.19
(+13.01%)
USD |
NASDAQ |
May 01, 16:00
1.70
+0.05
(+3.03%)
After-Hours: 20:00
Nektar Therapeutics Cash from Financing (Quarterly): 0.012M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.012M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.018M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.103M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.467M |
| March 31, 2022 | 0.938M |
| December 31, 2021 | 2.552M |
| September 30, 2021 | 3.663M |
| June 30, 2021 | 12.17M |
| March 31, 2021 | 17.86M |
| December 31, 2020 | 149.00M |
| September 30, 2020 | 1.531M |
| June 30, 2020 | -241.96M |
| March 31, 2020 | 11.08M |
| December 31, 2019 | 4.906M |
| September 30, 2019 | 6.249M |
| June 30, 2019 | 7.306M |
| March 31, 2019 | 4.894M |
| December 31, 2018 | 2.668M |
| September 30, 2018 | 3.859M |
| June 30, 2018 | 811.09M |
| March 31, 2018 | 34.35M |
| December 31, 2017 | 24.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 9.469M |
| June 30, 2017 | 9.468M |
| March 31, 2017 | 11.18M |
| December 31, 2016 | 190.95M |
| September 30, 2016 | 6.539M |
| June 30, 2016 | 1.753M |
| March 31, 2016 | 4.373M |
| December 31, 2015 | 119.06M |
| September 30, 2015 | 6.404M |
| June 30, 2015 | 4.727M |
| March 31, 2015 | 0.587M |
| December 31, 2014 | 29.86M |
| September 30, 2014 | 7.214M |
| June 30, 2014 | 2.044M |
| March 31, 2014 | 113.87M |
| December 31, 2013 | 2.164M |
| September 30, 2013 | 1.897M |
| June 30, 2013 | 0.629M |
| March 31, 2013 | -2.474M |
| December 31, 2012 | 0.21M |
| September 30, 2012 | -93.18M |
| June 30, 2012 | 0.273M |
| March 31, 2012 | 119.50M |
| December 31, 2011 | -0.306M |
| September 30, 2011 | 0.026M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-241.96M
Minimum
Jun 2020
149.00M
Maximum
Dec 2020
-1.269M
Average
1.531M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Stereotaxis Inc | 0.026M |
| Vanda Pharmaceuticals Inc | 0.00 |
| Cara Therapeutics Inc | 36.48M |
| Avid Bioservices Inc | 0.085M |
| Rigel Pharmaceuticals Inc | 0.486M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -47.05M |
| Cash from Investing (Quarterly) | 17.38M |
| Free Cash Flow | -193.47M |
| Free Cash Flow Per Share (Quarterly) | -0.2475 |
| Free Cash Flow to Equity (Quarterly) | -47.28M |
| Free Cash Flow to Firm (Quarterly) | -44.94M |
| Free Cash Flow Yield | -62.28% |